A trucut needle biopsy device that can be used to obtain specimens from the pancreas under EUS guidance has been developed.
This technique is safe, and appears to provide more accurate results than EUS-guided FNA.
|Overall diagnostic accuracy = 61%|
In this study, researchers from New York assessed its clinical utility in patients with solid pancreatic masses.
The team included 23 consecutive patients with radiologically detected solid pancreatic masses who underwent EUS-guided trucut needle biopsy.
They considered that pancreatic malignancy detected by EUS-guided trucut needle biopsy was the definitive diagnosis.
The researchers used additional diagnostic procedures and clinical course to establish or exclude the presence of malignancy in patients who returned a negative diagnosis.
The team was able to obtain pancreatic tissue in 74% of the patients.
Histopathologic evaluation of the pancreatic tissue revealed cancer in 12 patients.
The team was able to gain a CT-guided biopsy specimen in 4 of the 5 patients who had a negative EUS-guided trucut needle biopsy result. Of these, 2 patients were positive for adenocarcinoma.
The research team determined that the overall diagnostic accuracy of the EUS-guided trucut needle biopsy was 61%.
However, subgroup analysis of the 16 patients in whom EUS-guided trucut needle biopsy was successful and who were available for follow-up revealed a diagnostic accuracy of 88%.
Dr Alberto Larghi's team concluded, "This prospective study demonstrates that EUS-guided trucut needle biopsy, when performed transgastrically, is safe and accurate in the evaluation of patients with solid pancreatic masses".